DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics
DMAC Price/Volume Stats
Current price | $2.77 | 52-week high | $4.75 |
Prev. close | $2.65 | 52-week low | $1.46 |
Day low | $2.73 | Volume | 18,306 |
Day high | $2.81 | Avg. volume | 41,785 |
50-day MA | $2.90 | Dividend yield | N/A |
200-day MA | $2.93 | Market Cap | 105.14M |
DMAC Stock Price Chart Interactive Chart >
DiaMedica Therapeutics Inc. (DMAC) Company Bio
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Latest DMAC News From Around the Web
Below are the latest news stories about DIAMEDICA THERAPEUTICS INC that investors may wish to consider to help them evaluate DMAC as an investment opportunity.
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside PotentialIn this article, we discuss billionaire Lee Cooperman’s 10 stock picks with huge upside potential. To skip the details of Mr. Cooperman’s life and investment strategy, go directly to Billionaire Lee Cooperman’s 5 Stock Picks with Huge Upside Potential. Leon Cooperman is the true definition of a “self-made” person. He was born in the South […] |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica’s website at www.diamedica.com, in the Investor Relations section. Before the […] |
Q3 2023 DiaMedica Therapeutics Inc Earnings CallQ3 2023 DiaMedica Therapeutics Inc Earnings Call |
DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial ResultsProtocol Amendments and Increased R&D Spending Mark Q3 2023 |
DMAC Price Returns
1-mo | -6.73% |
3-mo | -2.46% |
6-mo | 7.36% |
1-year | 88.44% |
3-year | -69.56% |
5-year | -38.99% |
YTD | -2.46% |
2023 | 79.74% |
2022 | -57.64% |
2021 | -63.21% |
2020 | 109.07% |
2019 | 66.67% |
Loading social stream, please wait...